ArticleOncology and therapy2026
A Podcast Discussion on Medical Treatment in R/M-SCCHN in the Year 2025-Standard and Considerations for an Individualized Treatment.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) remains a disease with limited treatment options. Once salvage surgery or radiotherapy is no longer feasible, systemic medical therapy becomes the mainstay of treatment. This article discusses the general principles of systemic therapy, with a focus on key phase 3 clinical trials such as KEYNOTE-048 and EXTREME. The strengths and limitations of these studies are evaluated, and in the context of additional phase 2 trials, considerations are made regarding individualized treatment strategies based on patient-specific characteristics when selecting first-line therapy. Although there is limited evidence to define an ideal second-line therapy, switching the mechanism of action from the first-line treatment remains a reasonable approach. In conclusion, as of 2025, for fit patients, the choice of first-line therapy should be guided by PD-L1 combined positive score (CPS) and the clinical need for rapid remission, as well as other patients individual parameters. Second-line treatment decisions should be based on the mode of action used in the first-line setting-pending further clinical trials to establish optimal treatment sequencing. However, upcoming innovation within the landscape of medical treatment, with introduction of PD1 inhibition into the neoadjuvant setting, will need within the near future a reconsideration of hole treatment journey in head and neck. Podcast Audio (MP4 285072 KB).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.